New data to be presented on Enanta’s FXR agonist EDP-305 for
non-alcoholic steatohepatitis (NASH) and primary biliary cholangitis
(PBC)

New data to be presented on AbbVie’s investigational,
pan-genotypic, ribavirin-free HCV regimen that combines two distinct
antiviral agents, including glecaprevir, Enanta’s second protease
inhibitor

April 05, 2017 07:11 AM Eastern Time

WATERTOWN, Mass.--(EON: Enhanced Online News)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and
development-focused biotechnology company dedicated to creating small
molecule drugs for viral infections and liver diseases, today announced
that several abstracts regarding Enanta’s wholly-owned EDP-305
development program for NASH and PBC, as well as abstracts regarding
AbbVie’s investigational, pan-genotypic regimen of
glecaprevir/pibrentasvir (G/P) for the treatment of chronic hepatitis C
virus (HCV) infection, have been accepted for presentation at The
International Liver Congress™ (ILC) 2017, April 19-23, in Amsterdam.

Three poster presentations will demonstrate that EDP-305 is a potent
Farnesoid X Receptor (FXR) agonist that has been shown to reduce
fibrosis progression and improve non-alcoholic fatty liver disease
(NAFLD) activity scores (NAS) in a variety of preclinical models.

In addition, several oral and poster presentations will report data from
AbbVie’s G/P clinical development program. G/P is an investigational,
pan-genotypic, once-daily regimen that combines two distinct
direct-acting-antiviral (DAA) agents, glecaprevir, Enanta’s second
protease inhibitor, and pibrentasvir, AbbVie’s NS5A inhibitor.

The following abstracts regarding EDP-305 and G/P will be presented
during the International Liver Congress:

G/P is an investigational, pan-genotypic regimen that is being evaluated
by AbbVie as a potential cure in 8 weeks for HCV patients without
cirrhosis and who are new to treatment with direct-acting antivirals
(DAAs), who make up the majority of HCV patients. AbbVie is also
studying G/P in patients with specific treatment challenges, such as
patients with genotype 3 HCV, patients who were not cured with previous
DAA treatment and those with chronic kidney disease, including patients
on dialysis.

G/P is an investigational, once-daily regimen that combines two distinct
antiviral agents in a fixed-dose combination of glecaprevir (300mg), an
NS3/4A protease inhibitor, and pibrentasvir (120mg), an NS5A inhibitor.
G/P is dosed once-daily as three oral tablets.

Enanta Pharmaceuticals is a research and development-focused
biotechnology company that uses its robust chemistry-driven approach and
drug discovery capabilities to create small molecule drugs for viral
infections and liver diseases. Enanta’s research and development efforts
are currently focused on the following disease targets: non-alcoholic
steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory
syncytial virus (RSV) and hepatitis B virus (HBV).

Enanta has discovered novel protease inhibitors for use against the
hepatitis C virus (HCV). These protease inhibitors, developed through
Enanta’s collaboration with AbbVie, include paritaprevir, currently
marketed in AbbVie’s HCV regimens, and glecaprevir (ABT-493), Enanta’s
second protease inhibitor product, which AbbVie is developing as part of
its investigational, pan-genotypic HCV regimen of
glecaprevir/pibrentasvir (G/P) now in registration in the U.S., the E.U.
and Japan. Royalties and any further milestone payments from this
collaboration will provide funding for Enanta’s earlier development
programs, including its Phase 1 FXR agonist program for NASH/PBC, and
its preclinical programs for HBV and RSV. Please visit www.enanta.com
for more information on Enanta’s programs and pipeline.

Forward Looking Statements Disclaimer

This press release contains forward-looking statements, including
statements with respect to the prospects for AbbVie’s G/P regimen for
HCV and the prospects for Enanta’s further development of EDP-305.
Statements that are not historical facts are based on management’s
current expectations, estimates, forecasts and projections about
Enanta’s business and the industry in which it operates and management’s
beliefs and assumptions. The statements contained in this release are
not guarantees of future performance and involve certain risks,
uncertainties and assumptions, which are difficult to predict.
Therefore, actual outcomes and results may differ materially from what
is expressed in such forward-looking statements. Important factors and
risks that may affect actual results include: the efforts of AbbVie (our
collaborator developing glecaprevir) to obtain regulatory approvals of
its glecaprevir/pibrentasvir (G/P) combination and commercialize it
successfully; the regulatory and marketing efforts of others with
respect to competitive treatment regimens for HCV; regulatory and
reimbursement actions affecting G/P, any competitive regimen, or both;
the development risks of early stage discovery efforts in HCV and in new
disease areas such as NASH; Enanta’s lack of clinical development
experience; Enanta’s need to attract and retain senior management and
key scientific personnel; the need to obtain and maintain patent
protection for glecaprevir and Enanta’s other product candidates and
avoid potential infringement of the intellectual property rights of
others; and other risk factors described or referred to in “Risk
Factors” in Enanta’s most recent Form 10-K for the fiscal year ended
September 30, 2016 and other periodic reports filed more recently with
the Securities and Exchange Commission. Enanta cautions investors not to
place undue reliance on the forward-looking statements contained in this
release. These statements speak only as of the date of this release, and
Enanta undertakes no obligation to update or revise these statements,
except as may be required by law.

Recent Stories

WATERTOWN, Mass.--(EON: Enhanced Online News)--Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for v... more »

WATERTOWN, Mass.--(EON: Enhanced Online News)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for vi... more »

WATERTOWN, Mass.--(EON: Enhanced Online News)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for vi... more »